비오피오이드성 통증 치료 시장 성장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Non-Opioid Pain Treatment Market was valued at USD 47.2 billion in 2023 and is projected to grow at a CAGR of 7.3% from 2024 to 2032. This growth can be attributed to the rising incidence of chronic pain conditions and heightened concerns over opioid addiction and its risks. With a growing number of individuals facing disorders like arthritis, back pain, and neuropathic issues, the demand for effective pain management drugs has surged. With a growing shift towards safer pain management options, the demand for non-opioid treatments like analgesics and non-steroidal anti-inflammatory drugs has seen a significant rise, driving market expansion. This trend is largely fueled by patients seeking alternatives to opioids for effective pain relief without the associated risks.

The overall non-opioid pain treatment industry is classified based on drug class, medication type, indication, route of administration, distribution channel, and region. The non-opioid pain treatment market is segmented by drug class, including local anesthetics, NSAIDs, antidepressants, analgesics, anticonvulsants, and others. The NSAIDs segment led the market in 2023 and is projected to maintain its dominance with a CAGR of 7.1% throughout the forecast period. NSAIDs' widespread use and effectiveness in treating musculoskeletal, inflammatory, and acute pain contribute to their market leadership.

Being available both over-the-counter (OTC) and via prescription broadens their accessibility. NSAIDs' capability to alleviate pain and inflammation without the risks tied to opioids has made them a preferred choice for healthcare providers and patients alike. The oral segment, commanding a 42.9% market share in 2023, is poised to retain its lead throughout the analysis period. The oral route's dominance stems from its convenience, effectiveness, and broad availability.

Many patients, even those with acute or severe pain, prefer oral medications for their rapid relief and non-prescription nature. Heightened awareness of opioid risks has further nudged consumers towards safer oral alternatives. Consequently, the oral segment's established role in pain management and the rising demand for non-opioid solutions reinforce its dominance. In 2023, the U.S. led the North American non-opioid pain treatment market with a valuation of USD 19.2 billion, and significant growth is anticipated in the coming years.Several pivotal factors underpin the U.S.'s dominance in the North American market. There's a pronounced demand for alternative pain management solutions, largely driven by the ongoing opioid crisis and the widespread prevalence of chronic pain conditions. The U.S. also stands out for its innovation in non-opioid treatments, thanks to its advanced healthcare infrastructure, robust R&D investments, and the presence of top-tier pharmaceutical companies.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definitions
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising geriatric population and concern for pain management
    • 3.2.1.2 Increasing awareness of the risks associated with opioid use
    • 3.2.1.3 Expanding research funding and activities
    • 3.2.1.4 Growing advancements in the drug delivery system
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 Side effects and safety concerns
    • 3.2.2.2 Availability of alternative therapies and non-pharmacological approaches
• 3.3 Growth potential analysis
• 3.4 Pipeline analysis
• 3.5 Regulatory landscape
• 3.6 Porter's analysis
• 3.7 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Drug Class, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Nonsteroidal anti-inflammatory drugs (NSAIDs)
• 5.3 Local anesthetics
• 5.4 Antidepressants
• 5.5 Anticonvulsants
• 5.6 Analgesics
• 5.7 Other drug classes

Chapter 6 Market Estimates and Forecast, By Medication Type, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Over-the-counter (OTC)
• 6.3 Prescription

Chapter 7 Market Estimates and Forecast, By Indication, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Neuropathic pain
• 7.3 Post-operative pain
• 7.4 Chronic back pain
• 7.5 Cancer pain
• 7.6 Migraine
• 7.7 Arthritic pain
• 7.8 Muscle sprain/strain
• 7.9 Other indications

Chapter 8 Market Estimates and Forecast, By Route of Administration, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Oral
• 8.3 Topical
• 8.4 Injectable
• 8.5 Other routes of administration

Chapter 9 Market Estimates and Forecast, By Distribution Channel, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 Hospital pharmacies
• 9.3 Retail pharmacies
• 9.4 Online pharmacies

Chapter 10 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 10.1 Key trends
• 10.2 North America
  • 10.2.1 U.S.
  • 10.2.2 Canada
• 10.3 Europe
  • 10.3.1 Germany
  • 10.3.2 UK
  • 10.3.3 France
  • 10.3.4 Spain
  • 10.3.5 Italy
  • 10.3.6 Netherlands
  • 10.3.7 Rest of Europe
• 10.4 Asia Pacific
  • 10.4.1 Japan
  • 10.4.2 China
  • 10.4.3 India
  • 10.4.4 Australia
  • 10.4.5 South Korea
  • 10.4.6 Rest of Asia Pacific
• 10.5 Latin America
  • 10.5.1 Brazil
  • 10.5.2 Mexico
  • 10.5.3 Rest of Latin America
• 10.6 Middle East and Africa
  • 10.6.1 Saudi Arabia
  • 10.6.2 South Africa
  • 10.6.3 UAE
  • 10.6.4 Rest of Middle East and Africa

Chapter 11 Company Profiles

• 11.1 Amgen Inc.
• 11.2 Almatica Pharma LLC
• 11.3 Eli Lilly and Company
• 11.4 Fresenius Kabi AG
• 11.5 GlaxoSmithKline plc
• 11.6 Haleon group
• 11.7 Heron Therapeutics
• 11.8 Hyloris Pharmaceuticals
• 11.9 Johnson & Johnson Consumer Inc.
• 11.10 Neumentum Inc.
• 11.11 Novartis AG
• 11.12 Par Pharmaceutical, Inc.
• 11.13 Pfizer Inc.
• 11.14 Sanofi
• 11.15 Scilex Holding Company
• 11.16 Sun Pharmaceutical Industries Ltd.
• 11.17 Vertex Pharmaceuticals
• 11.18 WEX Pharmaceuticals Inc.